Results
A total of 316 subjects were recruited for the study, 251 subjects completed a baseline HS-Omega-3 Index assess- ment, and 157 subjects completed all aspects of the trial through 120 days. Non-completers were lost to follow-up. Adverse events reported were not serious and were deter- mined to not be associated with the study product. The mean age of subjects was 44.3 ± 0.9 years. Table 1 provides information on omega-3 supplement usage at baseline. No other demographic data were obtained.
The HS-Omega-3 Index increased from 6.1% (range of
3.1-11.8%) at baseline to 7.3% (3.7-13.3%) at 120 days
(p < 0.001, Figure 1). This represents an approximate
20% increase over baseline. The baseline score of ap- proximately 6% was higher than previously reported baseline scores of approximately 4%, as expected, reflecting regular use of omega-3 fatty acid supple- ments [24,25]. The mental composite score increased after 60 days and remained elevated through day 120
Results
A total of 316 subjects were recruited for the study, 251 subjects completed a baseline HS-Omega-3 Index assess- ment, and 157 subjects completed all aspects of the trial through 120 days. Non-completers were lost to follow-up. Adverse events reported were not serious and were deter- mined to not be associated with the study product. The mean age of subjects was 44.3 ± 0.9 years. Table 1 provides information on omega-3 supplement usage at baseline. No other demographic data were obtained.
The HS-Omega-3 Index increased from 6.1% (range of
3.1-11.8%) at baseline to 7.3% (3.7-13.3%) at 120 days
(p < 0.001, Figure 1). This represents an approximate
20% increase over baseline. The baseline score of ap- proximately 6% was higher than previously reported baseline scores of approximately 4%, as expected, reflecting regular use of omega-3 fatty acid supple- ments [24,25]. The mental composite score increased after 60 days and remained elevated through day 120
การแปล กรุณารอสักครู่..